Combretastatin A4
- CRC 87-09
货号: abs812141
货号-规格 | 货期 | 价格 | 数量 |
abs812141-5mg | 1-2周 | ¥506.00 | - + |
abs812141-10mg | 1-2周 | ¥824.00 | - + |
abs812141-25mg | 1-2周 | ¥1820.00 | - + |
abs812141-50mg | 1-2周 | ¥3299.00 | - + |

产品描述 | ||
描述 | Combretastatin A4是绑定 β-微管蛋白与 Kd 0.4 μ M 的微管针对代理。 | |
纯度 | >98% | |
储存/保存方法 | Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution. | |
基本信息 | ||
别名 | CRC 87-09 | |
可溶性/溶解性 | DMSO:63 mg/mL (199.14 mM) Ethanol:34 mg/mL (107.47 mM) | |
生物活性 | ||
靶点 | β-tubulin | |
In vitro(体外研究) | Combretastatin A4 inhibits the growth of MDA-MB-231, A549, Hela, HL-60, SF295, HCT-8, MDA-MB435, PC3M, OVCAR-8, NCI-H358M, and lymphocyte cells with IC50 of 2.8, 3.8, 0.9, 2.1, 6.2, 5.3, 7.9, 4.7, 0.37, 8, and 3.2 nM, respectively. 1 μM Combretastatin A4 inhibits tubulin polymerization by 35%, and 10 μM nearly completely blocks tubulin polymerization. Combretastatin A4 demonstrates great relative binding capacity, reaching 78% of colchicine binding. | |
In vivo(体内研究) | In NT2 and MDA-MB-231 mammary tumor model, administration of Combretastatin A4 (100 mg/kg, i.p.) induces a significant decrease in lipids R1 and a reduction in tumor pO2 measured by electron paramagnetic resonance (EPR) oximetry. Combretastatin A4 (100 mg/kg, i.p.) significant decreases the Ktrans in male NMRI mice. | |
参考文献 | ||
参考文献 | ||
温馨提示:本产品仅作科研实验使用,不支持临床等研究 |
- 实验方法 实验条件
共 0 张,还能上传 8 张 提交
- 提示: 尊敬的客户您好,如果您对我们的产品有什么疑问或想要了解的,可以点击“我要咨询”按钮填写您的疑问。
提交不成功?请联系info@absin.cn。
促销资讯 更多
订购信息
您可以从我们的授权经销商处购买absin产品或获得技术支持。若要查看您所在地区的经销商,请从以下的下拉列表中选择。